Back to Search
Start Over
APOA1 and APOB polymorphisms and apolipoprotein concentrations as biomarkers of risk in acute coronary syndrome: Relationship with lipid-lowering therapy effectiveness.
- Source :
-
Medicina clinica [Med Clin (Barc)] 2018 Jul 13; Vol. 151 (1), pp. 1-7. Date of Electronic Publication: 2017 Oct 07. - Publication Year :
- 2018
-
Abstract
- Background and Objective: Lipid metabolism alterations contribute to acute coronary syndrome (ACS). rs670, rs5070 and rs693 polymorphisms have shown to modify the risk of cardiovascular disease. Apolipoprotein A-I (ApoA-I) plays a major role in reverse cholesterol transport; apolipoprotein B (ApoB) contributes to accumulation of cholesterol in the plaque. The aim of this study was to investigate the association of rs670 and rs5070 polymorphisms of APOA1 and rs693 polymorphism of APOB with ACS and circulating levels of its proteins and find if ApoB/ApoA-I could be implemented as an independent parameter of risk for cardiovascular disease and as a biomarker of lipid-lowering therapy effectiveness in Mexican population.<br />Methods: Three hundred patients with ACS and 300 control subjects (CS) were included.<br />Results: Neither genotype nor allele frequencies of rs670, rs5070 and rs693 polymorphisms showed statistical differences between groups. Serum levels of ApoA-I (195 vs. 161.4mg/dL; P<.001) and ApoB (167 vs. 136.9mg/dL; P<.001) were significantly higher in CS compared with ACS; however, there was no genetic association. Unstable angina patients showed the highest ApoA-I levels (males: 176.3mg/dL; females: 209.1mg/dL).<br />Conclusion: The rs670, rs5070 and rs693 polymorphisms are not genetic susceptibility factors for ACS in Mexican population and had no effect on their apolipoprotein concentrations. In our population, ApoA-I, ApoB and HDL-C could be better biomarkers of cardiovascular risk and could indicate if statins doses reduce atherogenic particles properly.<br /> (Copyright © 2017 Elsevier España, S.L.U. All rights reserved.)
- Subjects :
- Acute Coronary Syndrome blood
Acute Coronary Syndrome drug therapy
Aged
Aged, 80 and over
Apolipoprotein A-I blood
Apolipoprotein B-100 blood
Biomarkers blood
Case-Control Studies
Cross-Sectional Studies
Female
Gene Frequency
Genetic Markers
Genetic Predisposition to Disease
Genotype
Humans
Hypolipidemic Agents therapeutic use
Male
Mexico
Middle Aged
Risk Factors
Treatment Outcome
Acute Coronary Syndrome genetics
Apolipoprotein A-I genetics
Apolipoprotein B-100 genetics
Polymorphism, Single Nucleotide
Subjects
Details
- Language :
- English; Spanish; Castilian
- ISSN :
- 1578-8989
- Volume :
- 151
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Medicina clinica
- Publication Type :
- Academic Journal
- Accession number :
- 28992985
- Full Text :
- https://doi.org/10.1016/j.medcli.2017.07.026